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Abstract
Recently, different technologies have been used to transform active pharmaceutical ingre‐
dients (APIs) into new dosage forms. Engineered drug delivery systems may modify 
biopharmaceutical properties of the API achieving either immediate or delayed release 
according to specific therapeutic needs. Particularly, preprogrammed release of oral for‐
mulations delivering the drug at expected times may be useful in chronotherapy of early 
morning pathologies. The conventional approach when dealing with such diseases is to 
administer NSAIDs two to three times daily. This approach does not allow to fit drug 
release with symptoms onset resulting in inefficient therapy and poor patient compli‐
ance. NSAIDs may be very effective if administered at least 4–6 h before the pain reaches 
its peak in the early morning. The solution could be to design delayed drug delivery sys‐
tems allowing one administration before going to sleep acting in the early morning. This 
chapter highlights new approaches in developing controlled delivery systems of NSAIDs 
potentially useful to treat both acute and chronic inflammation. The chapter illustrates 
the versatility of laminar jet break‐up technology (prilling) to produce gel beads able to 
control rate and time of drug delivery. A special focus will be on particle‐engineering 
strategies, i.e., prilling and prilling technique in tandem with microwave or supercritical 
fluid‐assisted drying.
Keywords: oral drug delivery, modified release dosage forms, chronotherapy, early morning 
pathologies, NSAIDs, prilling; hydrogels drying, dissolution, in vivo effectiveness
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1. Introduction
Any drug delivery system (DDS) may be defined as a system comprising:
• active pharmaceutical ingredients (APIs) and
• medical device or dosage form able to carry the drug inside the body.
To obtain a therapeutic response, the suitable amount of the drug must be delivered at the 
right time, in a safe and reproducible manner, to a specific target and at the required level. The 
distribution of the drug to tissues different from the sites of action and organs of elimination 
is a potential cause of toxicity.
Innovative drug delivery systems may overcome problems commonly related to conventional 
formulations. In fact, in the last few years, there is a continuous research in the development 
of engineered particles and systems for the targeted delivery and/or controlled release of 
APIs. These systems can protect the drug from degradation, realize controlled release, modify 
pharmacokinetics and biodistribution profiles, reduce clearance and side effects, and improve 
drug specificity. The administration of an old drug through an engineered delivery system 
may contribute to the improvement of the drug efficacy, safety, and patient compliance and 
may extend its conventional clinical applications [1, 2]. For example, in the treatment of both 
acute (i.e., postoperative pain, dental surgery) and chronic inflammatory diseases, immediate 
or delayed drug delivery systems are essential.
The development of delivery systems able to control and delay drug release is acquiring 
a growing interest with the recent advances in chronopharmacology. In fact, treating dis‐
eases affected by the circadian rhythms, such as “early morning pathologies” (EMPs) (rhi‐
nitis, rheumatoid arthritis, etc.) [3–5], requires a desired concentration of drug available at 
expected times [6, 7]. This effect may be assured by device releasing no drug within the time 
gap and delivering the optimal amount at certain point correspondent to symptoms peak 
[8–10]. Diseases with established circadian cycle show day–night patterns in the onset and 
symptoms exacerbation, usually with peaks in the morning and decrease throughout day 
[11]. Moreover, the plasma concentration of C‐reactive protein and interleukin‐6 has been 
shown to follow a circadian rhythm in chronic inflammatory‐based diseases such as rheu‐
matoid arthritis [12]. The main goals when dealing with such pathologies are as follows: 
stop inflammation, relieve symptoms, improve physical function and overall well‐being, and 
reduce long‐term complications.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) represent one of the most used classes of 
drugs in the management of EMPs. These molecules inhibit COX and prevent further forma‐
tion of prostaglandins and other related inflammatory mediators. Based on their mechanism 
of action, NSAIDs are useful as adjuvant therapy for the symptomatic management of the 
diseases, reducing inflammation and pain. NSAIDs employed to relieve symptoms are usu‐
ally administered to patients through oral route at different moment of the day (after awak‐
ening, after lunch, and during the night) through immediate‐release formulations. In this 
way, drugs are rapidly absorbed and explicate their action independently from the circadian 
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rhythms of hormones and cytokines responsible of EMP symptomatology. Such a conven‐
tional approach usually leads to ineffective therapy because drug liberation from the dosage 
form is not synchronized with the symptom peak resulting in an increase in side effects and, 
consequently, poor patient compliance. This explains why in the last few years a growing 
number of researchers have focused on the possibility to treat EMPs with a chronotherapeutic 
approach through oral route.
NSAIDs (i.e., indomethacin, aceclofenac, ketoprofen, flurbiporfen, and lornoxicam) are attrac‐
tive API to be modified in their formulation obtaining chronotherapeutic drug delivery sys‐
tems (ChDDSs) useful in the treatment of early morning pathologies [13]. For example, a 
pH‐responsive dual pulse multiparticulate dosage form containing ketoprofen was devel‐
oped and tested in rheumatoid arthritis. Results showed that this formulation was able to 
relieve circadian symptoms during midnight and early morning [14]. Levi et al. observed that 
the evening administration of indomethacin in a controlled release formulation was able to 
better control morning symptoms compared to the same formulation administered in other 
moment of the day [15].
Among different approaches used to design pharmaceutical dosage forms tailored to fol‐
low the human chronobiological rhythm [10, 16, 17], micro‐technologies have been applied 
as innovative and efficient tool [18, 19]. Several methods and techniques are potentially 
useful for the preparation of polymeric microparticles, such as spray drying, fluid bed 
coating, solvent evaporation, coacervation phase separation, prilling, etc. The choice of a 
specific microencapsulation technology is related to the polymer nature, the chemical fea‐
tures of drug, the desired particles size, as well as to the reproducibility and ease to scale 
ability of the method [20].
1.1. Prilling technique
Among the different processes used for the preparation of ChDDSs, prilling or laminar jet 
breakup technique is an emerging process able to produce homogenous microparticles with 
high drug content and controlled release properties. Prilling is a vibration‐based technol‐
ogy consisting in breaking apart a laminar jet of polymer solution into a row of monosized 
drops by means of a vibrating nozzle device (Figure 1) [21, 22]. Once the droplets are formed, 
the gelation/consolidation step follows in order to prevent either the aggregation of polymer 
droplets or the undesired leakage of encapsulated drugs. The chemical nature of the droplets 
(dispersed phase) determines the consolidation step, in which the droplets are transformed 
into solid microparticles known as gel‐beads; this procedure can involve temperature modifi‐
cation, chemical reactions, and mainly ionic cross‐linking (ionotropic gelation).
Several variables in prilling can affect droplet size and size distribution as polymer concentra‐
tion and flow rate [23, 24], frequency of vibration, as well as falling distance. In fact, using high 
wavelengths of the jet breakup and reducing the falling distance to the hardening solution, 
the drop coalescence can be reduced. Thus, smaller nozzle diameters and higher frequencies 
increase the possibility of coalescence [22]. The frequency is usually kept as low as possible 
in order to avoid the formation of satellite droplets leading to a broader size range [21]. The 
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production of microparticles by the vibrating nozzle device is highly reproducible, is time‐
saving, and can be performed under aseptic and scaled‐up conditions [25]. The acoustic jet 
excitation process involved in prilling was patented for production of uniform microspheres 
of alginate [26], collagen [27], and PLGA [28, 29]. The scale‐up of the vibration process may 
be done by using a multinozzle system (Figure 2) without changing other process parameters 
such as flow rate and the vibration frequency [30]. However, the arrangement of the nozzles 
which must ensure equal jet formation and equal pressure drops between the nozzles is an 
Figure 1. Prilling apparatus (Nisco Inc.) at the Department of Pharmacy, University of Salerno.
Figure 2. Multinozzle system BRACE GmbH [32].
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important parameter [30]. The pilot apparatus using this technique is now being sold by Brace 
GmbH (Germany), Nisco Inc. (Switzerland), and Inotech AG (Switzerland) [22, 31].
The ionotropic gelation, a highly used consolidation step, is based on the ability of polyelec‐
trolyte polymers (alginate, pectin, chitosan, and gellan gum) to cross‐link in the presence of 
counter ions [32, 33]. Divalent cations (Cd2+, Co2+, Cu2+, Mn2+, Ni2+, Pb2+, and Zn2+) are suitable 
cross‐linking agents with the exception of Mg2+ [32, 33]. The binding affinity depends on the 
chemical composition of the selected polysaccharide, which varies with the source, the char‐
acteristics of the polyvalent cations (i.e., ionic radius and coordination number), and the pres‐
ence of water of hydration surrounding cross‐linking ions [32].
After the production stage, hydrogels require to be dried to avoid chemical or microbiologi‐
cal degradation [34]. Drying processes may have a different impact on the final properties of 
the dried product (solute migration, polymorphism, damages by overheating, and structural 
modifications). Therefore, the selection of drying technique has a crucial role to determine the 
textural of the final product and to avoid altering its quality.
2. Prilling‐based tandem techniques to produce NSAIDs controlled 
delivery systems
In this chapter, we described three different prilling‐based tandem techniques to produce 
chronotherapeutic dosage forms delivering NSAIDs. The techniques are based on the combi‐
nation of prilling with conventional drying, microwave‐assisted drying, or supercritical fluid‐
assisted drying [35].
2.1. Prilling in tandem with conventional drying
To effectively formulate NSAIDs targeting EMPs, prilling microtechnology in combination 
with conventional drying was used. The traditional drying of hydrogels is based on the evap‐
oration of the solvent; when the solvent inside the pores of the material evaporates, they are 
subjected to high tension, which causes the partial collapsing of the structure and the wet 
gel is changed in the so‐called “xerogel.” Usually, this process is rapid, cheap, and easy to 
perform. Furthermore, recent studies [36–39] suggested that the opportune setup of some 
drying parameters may allow the production of materials with unique structural properties, 
i.e., microporous, micro‐mesoporous, or micro‐macroporous systems.
In this section, we described the combination of prilling technique with conventional drying 
to obtain xerogel‐based beads loaded with ketoprofen, ketoprofen lysine salt, and piroxicam.
2.1.1. Ketoprofen‐loaded xerogels as new ChDDSs: design and in vitro/in vivo characterization
Ketoprofen is a NSAID commonly used in some EMPs as rheumatoid arthritis for its anal‐
gesic and anti‐inflammatory features. Nevertheless, many collateral effects, such as gastric 
troubles, restrict its therapeutic benefit. Furthermore, its short biological half‐life (t1/2= 2.1h) 
NSAIDS: Design and Development of Innovative Oral Delivery Systems
http://dx.doi.org/10.5772/intechopen.68240
37
and the need of a high number of daily administrations enhance side effects especially for 
chronic therapy. For these reasons, ketoprofen is a good candidate for the development of 
controlled release formulations, able to provide drug release at predetermined rate and time, 
targeting intestine [21, 40].
2.1.1.1. Approach #1
With the aim to delay ketoprofen release as needed for chronotherapy of EMPs, we designed 
a gel‐beads formulation for delayed delivery of ketoprofen release and in vivo absorption for 
several hours [41, 42].
2.1.1.1.1. Methods
The engineered particles were produced by prilling/ionotropic gelation technique using algi‐
nate as gastroresistant polymer carrier and zinc as cross‐linking agent. Particularly, Zn2+ was 
also selected for its anti‐oxidant properties that may boost the efficacy of the anti‐inflam‐
matory drug encapsulated in the polymeric matrix [43, 44]. After the production, hydrated 
particles were then exposed to standard room conditions (22 °C; 67% RH) for 12–18 h until 
constant weight was reached obtaining xerogel beads. During the work, different experi‐
ments were conducted for the optimization of process parameters in order to obtain ketopro‐
fen gel‐beads with desired properties and performances (Table 1). Beads micromeritics, solid 
state, and drug release properties were studied using established method (SEM, DSC, USP 36 
Paddle Dissolution).
2.1.1.1.2. Results and discussion
Formulation AK_5 obtained with the highest ketoprofen content (alginate 2% w/w; ketopro‐
fen–alginate ratio = 1:5) showed the highest value of both actual drug content (ADC 9%) and 
encapsulation efficiency (EE 53%). It is interesting to point out that ADC and EE were related 
to the drug/polymer ratios suggesting that the incorporation of a great quantity of ketopro‐
fen (into the feed solutions) could induce, during the gelation process, the establishment of 
intermolecular interactions (as hydrophobic or hydrogen bonding) able to stabilize the “egg‐
box” structure, leading to a more strong cross‐linked matrix. All K‐loaded beads exhibited a 
remarkable reduction in mean diameter in comparison to blank beads with diameters’ values 
Alginate concentration = 2.0% (w/w) Gelling cations = Zn2+
Drug/polymer ratio = 1:20–1:10–1:5 Gelling time = 2 min
Ø nozzle = 400 μm pH gelling solution =1.5
Ν = 0.350 kHz A = 100% Flow rate = 5 mL/min
Composition of the aqueous feed solutions, prilling parameters (nozzle diameter Ø, frequency N and amplitude A of 
vibration, and flow rate), gelling solution variables (divalent cation for ionotropic gelling, pH of the gelling solution and 
cross‐linking time).
Table 1. Optimized prilling operative conditions.
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in the range of 1.7–1.8 mm. Stabilization of the polymer matrix influenced beads shape after 
the drying process. In particular, SEM analyses confirmed that K‐loaded beads had almost 
spherical shape according to K loading (Figure 3).
Pilot dissolution tests of all formulations were performed by conventional vessel meth‐
ods (USP Apparatus 2, paddle) [45] using a classic pH change method, providing essential 
information and recommended in various guidelines [46] as a first choice for the in vitro 
dissolution testing of controlled/modified release formulations [47]. Results showed that 
AK_5 exhibited a gastroresistant profile followed by a slow and extended release of K in SIF 
(Figure 4A). Probably, the intermolecular interactions combined to the high zinc ability to 
cross‐link alginate moieties, led to a strong polymeric matrix for AK_5 able to better control 
the drug diffusion. The dissolution profile of this formulation was deeply studied using the 
USP apparatus 4 (flow‐through, open‐loop configuration), because, as reported in literature, 
it is able to accurately mimic in vivo hydrodynamics and consequently better predict the real 
in vivo behavior of oral formulations [48, 49]. USP apparatus 4 analysis (Figure 4B), con‐
firmed the enteric release ability of AK_5 beads showing in SIF a slower ketoprofen release 
compared to USP 2 analysis. The observed differences were mainly due to the particular 
hydrodynamic conditions realized by the USP 4 apparatus (no agitation mechanism and 
constant exposure to the formulation to a laminar flow) that are very similar to the in vivo 
gastrointestinal conditions [50, 51].
Figure 3. SEM microphotographs of dried Zn‐alginate beads formulations: (a) blank beads, (b) AK_20, (c) AK_10, and 
(d) AK_5.
Figure 4. (A) Release profiles of K raw material (‐▾‐) and K‐loaded formulations AK_20 (‐⚬‐), AK_10 (‐▪‐), and AK_5 
(‐♢‐), performed by USP Apparatus 2; (B) release profiles comparison of AK_5 obtained by USP Apparatus 2 (‐♢‐) and 
USP Apparatus 4 (‐♦‐), using a pH change assay. Mean ± SD; (n=6).
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To verify whether the in vitro drug release may be correlated to a prolonged anti‐inflamma‐
tory effectiveness, AK_5 (ketoprofen equivalent dose of 3 mg/kg) was tested in vivo using a 
carrageenan‐induced acute edema in rat paw (male Wistar rats). Its activity was compared to 
the activity of pure drug. In detail, samples were administered to rats at the time 5, 3, and 0.5 
h before the injection of the phlogistic agent, and paw volume was measured plethysmogra‐
phycally at the time zero, each hour for 6 h, and at 24 h.
As shown in Figure 5, AK_5 exhibited a prolonged anti‐inflammatory effect expressed as 
paw volume reduction, after oral administration in rats in comparison with the control. 
Unformulated ketoprofen (3 mg/kg) reduced rat paw edema only with a contemporary 
administration (0.5 h before carrageenan injection), without any effect at t=3 or 5 h before 
the phlogistic agent injection. Blank zinc‐alginate beads, administered to rats at the same 
time points, did not interfere with the inflammatory process. AK_5 administered 3 or 5 h 
before edema induction still showed a significant anti‐inflammatory activity reducing maxi‐
mum paw volume (3–4 h) in response to carrageenan injection, therefore reflecting its drug 
delayed release (Figures 4 and 5). Moreover, the prolonged in vivo anti‐inflammatory effect 
may be related to the mucoadhesive features of alginate particles able to reduce the ketopro‐
fen absorption in the gastrointestinal tract [52].
Being the optimized formulation AK_5 able to delay in vivo K release and absorption up to 
6–7 h, it can be considered a potential chronotherapeutic system for the delivery of K. 
Opportunely timing its administration is possible to match the disease rhythms and to control 
early morning symptoms in inflammatory‐based EMPs.
Figure 5. Edema volume reduction obtained administering AK_5 and pure K per os to rats 5h (‐▪‐_AK_5 and ‐∇‐_K) and 
3h (‐▪‐_AK_5 and ‐∆‐_K) before carrageenan injection compared to control (‐⚬‐); mean ± SD (n=8). **P ≤ 0.01, ***P ≤ 0.001 
compared with control.
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2.1.1.2. Approach #2
These preliminary results have been the starting point to further improve technological prop‐
erties of gel‐beads’ formulations in terms of ketoprofen loading and release performances. 
Therefore, in the following study, we designed a more complex system based on core/shell 
particles (double‐layered particles) consisting of a Zn‐pectinate core loading NSAID and an 
enteric shell of Eudragit S100 (anionic copolymer of methacrylic acid and methyl methacrylate 
insoluble in acid pH) [53]. Among different commercially available pectins, we focused our 
attention on amidated low methoxy (ALM) pectin (esterification degree 24% and amidation 
degree 23%) that, showing high hydrophobic interactions between pectin chains and inter‐
nal hydrogen bonding between amide groups, is able to stabilize the egg‐box structure [54]. 
Pectins are usually classified on the basis of their degree of esterification (DE) and divided in 
high methoxyl (HM_DE > 50%) and low methoxyl pectin (LM_ DE< 50%). The latter are the 
most suitable for the development of oral controlled drug delivery systems. In addition, as 
reported in the literature, the presence of amide groups in low methoxyl pectin enhances the 
gel‐forming ability, the stability under different pH conditions improving, consequently, the 
possibility to control drug release [55].
2.1.1.2.1. Methods
Ketoprofen‐loaded core particles based on Zn‐pectinate matrix were produced by prilling tech‐
nique using optimized operative conditions [53]. Beads micromeritics, solid state, and drug release 
properties were studied using established method (SEM, DSC, USP 36 Paddle Dissolution).
2.1.1.2.2. Results and discussion
Formulation BK_5 (Pectin 6% w/w, drug/polymer ratio = 1:5), obtained with the greatest 
amount of drug, showed the best morphology and the highest EE value (86.7%). In fact, as 
also observed for alginate beads loaded with ketoprofen [41], the drug and its amount play an 
important role during the gel matrix formation conditioning and therefore affect technologi‐
cal and mechanic properties of the final dosage form.
To obtain information about in vitro release performances, this formulation was tested 
through a USP apparatus II using a classic pH change method. As expected, monolayered Zn‐
pectinate beads were not properly effective in retaining drug in simulated gastric fluid (22.2% 
of the drug was released in 120 min). Their solubility and swelling properties in aqueous 
media allow a prompt release of NSAID after the pH change of the dissolution fluid (complete 
drug release was achieved in 180 min). The chronotherapeutic system was obtained by coat‐
ing zinc‐pectinate core (BK_5) with a Eudragit S100® shell. The core–shell system BK_5/E40, 
obtained applying coating in the amount of 40% (w/w), showed a strong delay of ketoprofen 
release in SGF followed by a slow and controlled release in SIF (Figure 6). This system was 
able to significantly reduce ketoprofen release in acidic environment from 22.2% (BK_5) up to 
7.3% and to prolong its release in simulated intestinal medium. In fact, after the pH change, 
drug release was completed in approximately 3 h (t=300 min) rather than in 1 h (t= 180) as for 
BK_5. Only after the dissolution of the enteric shell in SIF, the zinc‐pectinate core is exposed to 
the fluid and pectin chains begin the hydrolysis, releasing slowly the loaded drug. This profile 
appears feasible and potentially effective for chronotherapy of early morning pathologies.
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2.1.2. Ketoprofen lysine salt‐loaded beads: design and characterization
Although several studies have been reported on polysaccharide hydrogels entrapping the 
nonsoluble form of ketoprofen [21, 41, 53, 56], few data are available on its L‐lysine salt show‐
ing better pharmacokinetics and tolerability, enhancement in the rate of absorption, reduction 
of the onset of therapeutic effect, as well as improvement of the gastric tolerance [57]. The 
major issue encountered when dealing with such API is the high aqueous solubility prevent‐
ing the formulation of delivery systems with high encapsulation efficiency values and, above 
all, effective controlled release properties [58].
Thanks to the expertise grew up in the last few years, we proposed alginate and ALM pectin 
as carriers and release tailoring agents for the development by prilling of chronotherapeutic 
system loaded with KL. As highly soluble drugs in hydrogels exhibit poor drug entrapment 
and ineffective control in drug release, many formulation variables have been investigated to 
find the optimal ones.
2.1.2.1. Methods
Beads were prepared using Zn2+ as a gelling agent and optimizing cross‐linking conditions 
as follows: temperature (4–5°C), pH (1.5) and gelling time (2 min). Different formulations 
were produced setting polymer concentration at 2.0% and 6.0% w/w for alginate (A) or pec‐
tin (B), respectively, and varying drug‐polymer ratio as follows: 1:20 (KL_20), 1:10 (KL_10) 
and 1:5 (KL_5). Drying process of the hydrated beads was conducted by exposing them to 
standard room conditions as previously described. Beads micromeritics, solid state, and 
drug release properties were studied using established method (SEM, DSC, USP 36 Paddle 
Dissolution).
Figure 6. Drug release profiles of core–shell system BK5/E40 (‐●‐) compared to monolayer formulation BK5 (‐▴‐) and 
SEM picture of a cryo‐fractured core–shell particle BK5/E40 with magnification of the core–shell structure.
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2.1.2.2. Results and discussion
ADC and EE values were related to the specific polymeric material used (A or B) and drug 
polymer ratio. The higher the drug polymer ratio, the higher the EE. KL encapsulation was 
higher in pectin (81–94%) than in alginate (39–49%) beads. This effect could be related to the 
low molecular weight of pectin able to improve the hydrogel structure [59, 60]. The produced 
particles were cryofractured and analyzed by SEM (Figure 7) with the aim to study the effect 
of alginate or pectin on the inner structure. Pectin‐made beads showed a uniform and more 
compact inner structure with regard to alginate‐based particles. Indeed, KL crystals resulted 
effectively included in the pectin matrix, whereas, for alginate beads, they resulted being 
distributed on the external layer (Figure 7). This effect may be due to the formation of several 
intermolecular hydrogen bonds and hydrophobic interactions between KL and pectin amino 
residues able to deeply stabilize the egg‐box structure [61, 62]. The strong hydrogel network 
can determine a high shrinkage of the volume after drying process, leading to a significant 
reduction in mean diameter of the beads.
Results of dissolution tests (Figure 8) revealed that all KL‐alginate beads provided fast and 
complete drug release in acidic medium, without any lag time, in 120 min. On the contrary, all 
pectin‐based beads were able to achieve KL sustained release. The specific drug release profile 
from each formulations’ series perfectly matches with beads morphology and structure data 
obtained by SEM investigation. The faster release of KL‐alginate beads in SGF was related to 
KL crystals on the particle’s surface and to the higher permeability of alginate matrix. Instead, 
Zn‐pectinate beads showed a reduced swelling and erosion process in gastric environment 
as effect of their more compact texture [53, 63]. These data are consistent with recent litera‐
ture studies, confirming the higher suitability of ALM‐pectin to produce xerogel beads with 
improved technological properties compared to alginate [64, 65].
To improve delayed and sustained release performances, BKL_5 was selected as starting material 
for the preparation of a drug delivery platform made up by DR® capsules and BKL_5 (BKL_5/
DR caps). Although gelatin capsules disaggregate after few minutes in  simulated  biological 
Figure 7. SEM microphotographs of cryo‐fractured xerogel beads: (a) AKL_5 and (b) BK_5.
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 fluids, the selected capsules (DR®) can prolong the disaggregation step up to 75–90 min delay‐
ing the hydration process of BKL_5 beads in SGF. The optimized platform (BKL_5/DR caps) sig‐
nificantly reduced KL dissolution in SGF and showed a slower release in intestinal environment 
(Figure 9). This platform reduced KL release in SGF from 31.9 to 8.8% and prolonged its release 
in intestinal simulated fluid until 4.5 h (t=270 min) compared to 1 h (t=180 min) as observed for 
BKL_5. Only after the disaggregation of the capsule’s body, beads are exposed to dissolution 
medium, starting later the dissolution process.
Figure 9. KL release profiles of BKL_5 (A) compared to the optimized platform BKL_5/DR caps (B).
Figure 8. KL release profiles of formulations AKL_5 (‐♦‐), BKL_20 (‐▪‐), BKL_10 (‐●‐), and BKL_5 (‐▾‐) compared to KL 
raw material (‐▴‐).
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Platform BKL_5 /DR caps may be potentially useful for the oral administration of highly solu‐
ble NSAIDs such as ketoprofen lysinate in the chronoterapeutic treatment of EMPs.
2.1.3. Piroxicam‐loaded core/shell beads as new ChDDS: design and characterization
Piroxicam (PRX) is a NSAID of the oxicam class largely used to treat EMPs. PRX is included 
in the class II of the Biopharmaceutical Classification System as ketoprofen; however, it pos‐
sesses different physical–chemical properties such as higher melting point and ampholytic 
nature. Thus, it may exist in different ionic forms at physiological pH [66]. PRX is rapidly 
and completely absorbed following oral administration (recommended dose in adults is 20 
mg daily) and exhibits a long half‐life (24‐48h). However, its elimination is impaired in some 
elderly people [67], who represent the majority of patients affected by rheumatic diseases, 
resulting in a high inter‐individual variability in the steady state plasma levels. Therefore, 
sustained release dosage forms capable of steady release of PRX over prolonged periods may 
overcome such variability due to erratic drug elimination [68].
In the case of PRX, we investigated the possibility to develop multiparticulate beads based 
on a blend of natural polysaccharides (monolayered particles) or a combination of polysac‐
charides with other polymers (double‐layered particles). As discussed, beads based on single 
polysaccharide matrix may exhibit a premature release of the drug in the upper part of the 
GIT, making necessary the use of additional technological actions such as an enteric coating 
[53] or an envelopment in capsular devices [58]. However, a gel‐matrix based on the combina‐
tion of two or more polymers may be very effective [69].
2.1.3.1. Methods
Two series of piroxicam‐loaded particles were produced using pectin/alginate (B/A) blends 
or pectin alone as carrier material. Several formulations were designed varying polymer total 
concentration between 4.0 and 6.0% (w/w), pectin alginate ratio from 10:0 to 10:2 and set‐
ting drug/polymers ratio at 1:20 (PRX_20) or 1:15 (PRX_15). Other operative conditions were 
set accordingly to previous experiments in order to obtain spherical hydrated beads with 
tough polymer matrix, smooth, and regular surface [69]. Beads micromeritics, solid state, and 
drug release properties were studied using established method (SEM, DSC, USP 36 Paddle 
Dissolution).
2.1.3.2. Results and discussion
High encapsulation efficiency (EE ranging from 62 to 93%), correlated to the increase of the 
polymer concentration in the feed, was achieved especially for BPRX_20, formulated with 
pectin alone. SEM analyses (Figure 10) highlighted that no crystals of piroxicam were visible 
on the surface, suggesting the drug complete entrapment within the polymeric matrix. Good 
micromeritics and encapsulation efficiency proposed the pectin‐based formulation BPRX_20 
as a starting point to develop a more efficient technological platform applying the two step 
core–shell approach previously tested for ketoprofen.
Beads BPRX_20 were coated by immersion with Eudragit® S100 to obtain an enteric coating 
able to avoid the erosion of the core pectin matrix and protect the drug in acidic medium [69]. 
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Core/shell beads BPRX_20/E40 showed a drug release profile typical of gastro‐resistant oral 
dosage forms, releasing less than 20% of piroxicam in SGF. In SIF, this formulation released 
approximately 50% of the loaded drug after 1 h achieving complete PRX release in approxi‐
mately 5 h (Figure 11).
On the basis of these results, we can conclude that prilling technique in combination with an 
enteric coating is a very promising and simple two‐step method to formulate core/shell beads 
as chronotherapeutic agents.
Figure 11. Release profiles of uncoated BPRX_20 (♢) and Eudragit®‐coated beads formulations BPRX_20 _40 (♦), with 
regard to pure piroxicam (▪). Mean ± SD; (n=6).
Figure 10. SEM microphotographs of pectin/alginate (a) and pectin beads (b) loaded with PRX produced by prilling and 
dried at room conditions.
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Core–shell particles may also be obtained using a novel single step approach based on co‐
axial prilling technique. Core–shell systems composed of alginate (A) in the outer layer and 
pectin/piroxicam (B/PRX) as core were designed [70]. This innovative method employs multi‐
ple concentric nozzles to produce a smooth coaxial jet comprising polymer annular shell and 
core material, which are broken up by acoustic excitation into uniform core–shell droplets 
and gelled into a cross‐linking solution. Alginate and pectin/PRX suspensions were pumped 
out through coxial nozzles with inner and outer diameters of 400 and 600 μm, respectively. 
Using volumetric flow rate of 10 ml/min, vibration frequency of 350 Hz and 100% amplitude 
of the vibration, the two viscous polymers suspensions subjected to prilling immediately 
formed droplets, which were dripped in a gelling Zn2+ bulk (Zn2+ concentration 10% w/v, pH 
1.5 and cross‐linking time 8 min). Schematic illustration of the core–shell process is shown 
in Figure 12.
Results showed that satisfying encapsulation efficiency values were obtained for the produced 
formulations (EE 58–93%). However, it is interesting to point out that EE for coated beads was 
related to shell integrity. In fact, formulation A/B_PRX10 (core/shell ratio 4:1 and PRX/pectin 
ratio 1:10) showing the most homogeneous coating presented very high EE (86.3%). The for‐
mation of complete alginate shell was able to prevent the piroxicam leaking from the drop‐
lets into the gelling medium during the polymer cross‐linking phase; accordingly, a better 
 entrapping of the drug within the core was obtained. The critical factor to obtain beads with 
regular shell was found to be the ratio between the nozzle viscosity of inner and outer poly‐
mer solutions (μ
c
/μs). In fact, when nozzle viscosities ratio was less than 4, particles showed 
Figure 12. Schematic reproduction of prilling technology in coaxial configuration.
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irregular or uncompleted alginate coating around the pectin core, whereas values over six 
matched with completely layered beads. During the droplet formation, the outer solution 
must be able to completely enclose the inner one. Therefore, the decrease in the alginate con‐
centration and, subsequently, the decrease in the nozzle viscosity determine a regular core/
shell beads formation [71].
To better understand the influence of drug content on polymeric matrix, cryofractured beads 
were also analyzed by fluorescent microscopy (FM). FM images of PRX‐loaded pectin beads 
exhibited fluorescent spots due to crystals of piroxicam homogeneously encapsulated within 
the Zn‐pectinate matrix (Figure 13a–c). FM analysis also proved that PRX core/shell beads, 
with B/A mass ratio of 4:1, presented the most homogeneous coating and, interestingly, 
showed that drug was confined into the particle inner matrix without any leaching into the 
alginate shell.
As reported elsewhere, Refs. [72–74] monolayered pectin beads act as a fast release formula‐
tion delivering approximately 50% of PRX in simulated gastric fluid and allowing the total 
drug release in SIF, after pH change, in approximately 2 h (Figure 14). On the contrary, core 
shell beads A/B_PRX10 release approximately 30% of PRX in SGF, achieving 100% in 5 h. The 
alginate shell decreases the initial burst effect, delaying both particles dissolution and drug 
diffusion in the simulated gastric fluid.
This study demonstrated that co‐axial prilling technique can be used as a novel single‐step 
approach for the manufacturing of core–shell particles containing NSAIDs. The most critical 
process parameter to obtain uniform double‐layered particles was identified in the ratio between 
Figure 13. Fluorescent microscopy pictures of cryofractured PRX‐loaded formulations: (a) uncoated Pct beads and (b 
and c) B/A beads.
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inner and outer solution viscosities. The optimized core/shell (A/B_PRX10) beads can be consid‐
ered either as a self‐consistent dosage form or as a formulation to be hosted in suitable gastro‐
resistant capsule with the aim to further delay drug release meeting the requirements of EMPs.
2.2. Prilling in tandem with microwave‐assisted drying
Hydrogel drying can also be conducted using alternative methods to conventional techniques. 
Each drying process has a different impact on structural characteristics of the dried beads espe‐
cially on release properties. Particularly, in recent years, microwaves (MW) assisted heating has 
gained great interest in many applications with special reference to pharmaceutical processing. 
Several benefits can be obtained from technologies such as short processing time, better prod‐
ucts uniformity and yields, energy saving, reduced production costs, as well as the ability to 
confer unique structural characteristics to the end materials. Recently, MW heating technology 
has been shown to be useful in the design of single‐unit dosage forms such as solid dispersion, 
granules, and tablets [75–78]. Moreover, in the case of dextran‐based formulations (i.e., algi‐
nate, pectin, and chitosan), MW irradiation leads to obtain xerogels with modified drug release 
properties due to the extent of polymer cross‐linking and drug‐excipient complexation [79, 80].
The efficiency of MW‐assisted drying process is strongly influenced by dielectric, thermal, 
and other physical properties, as well as by moisture content of the irradiated material [81–
84]. Under the influence of microwaves, the highly polarizable H
2
O molecules can rotate rap‐
idly in an attempt to align themselves with the alternating field, determining the frictional 
heat that promotes water evaporation. This forms the basis of microwave‐assisted drying.
In view of these considerations, it is expected that MW heating is suitable to dry dissipative 
materials as carbohydrate‐based hydrated beads manufactured by prilling. Therefore, the 
feasibility of joining prilling and MW‐assisted treatments as a tandem technique was inves‐
tigated to produce alginate‐based xerogels with tailored NSAIDs release. Particularly, in this 
case, we selected two NSAIDs: ketoprofen (K) and piroxicam (PRX).
Figure 14. Release profiles of PRX raw material (‐*‐), monolayered pectin beads (‐▪‐) and core/shell beads A/B_PRX10 (‐♦‐), performed using a pH change assay. Mean ± SD (n = 6).
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2.2.1. Release characteristics of ketoprofen‐loaded beads obtained by prilling‐dielectric treatments
As described by Auriemma et al. ketoprofen‐loaded beads were obtained using prilling in tan‐
dem with dielectric treatments [85].
2.2.1.1. Materials and methods
Hydrated beads loaded with ketoprofen were manufactured by prilling and dried using 
MW‐assisted heating under different radiation conditions (MW, power level I–IV) as con‐
trol beads dried by air‐bulk heating (tray oven) at 105°C and air‐bulk room conditions were 
prepared. During the research, we studied the effects of different MW irradiation levels on 
particles micromeritics (i.e., morphology, size distribution, matrix porosity, and solid state 
of the loaded drug) and drug release behavior using established method (SEM, DSC, USP 36 
Paddle Dissolution).
2.2.1.2. Results and discussion
Drug content and encapsulation efficiency were not influenced by the drying method. 
Particularly, ADC increased from 8 to 25% in accordance with the increasing of drug/poly‐
mer ratio (1:10 up to 1:3), and EE was remarkably high (over 93%) without any variation due 
to the drying process. In addition, as shown in Figure 15, the regime of MW irradiation had 
an important role on drying curves. MW irradiation process conducted at levels IV and III 
showed a drying rate essentially superimposable in the first 15 min. This might be due to the 
penetrative and volumetric heating nature of microwaves interesting the water migration from 
the inside out of the particles [86]. On the contrary, weaker irradiations needed prolonged 
times to eliminate water from particles. Conventional heating methods require, instead, even 
more prolonged process times (12–18 h at room conditions and 7 h for tray oven). This effect is 
probably due to the high thermal capacity and the low thermal diffusivity of hydrated beads.
Morphological analysis showed main differences in particle mean diameters for beads dried 
at different regime of MW irradiation. In fact, beads dried in MW continuous regime (level IV) 
exhibited the highest mean diameter (around 1.4 mm), while beads exposed to the weakest 
irradiation (level I) presented the lowest mean diameter (1.3 mm). Surface roughness as well 
as the number of cracks and craters on beads surface increased when level IV MW regime was 
used as shown by SEM analysis (Figure 16b, c).
Moreover, ketoprofen was in the amorphous state when drying was conducted at MW level 
IV due to the harsh regime of irradiation [87], whereas only few crystals without any trace of 
amorphous drug on the particle surface were observed for MW level II dried beads, as con‐
firmed by X‐ray analysis (Figure 17).
Regarding release properties, dielectric treatments provided a modulation of drug release 
(Figure 18). While beads dried at room conditions showed the typical behavior of enteric for‐
mulations, MW‐treated beads at level IV acted as a conventional release formulation exhibit‐
ing a fast drug release without any lag time. In this case, the presence of solid ketoprofen and 
cracks on the bead surface (SEM images in Figure 16) allow an immediate release of the drug 
(45–50% in SGF) and a faster and continuous penetration of the dissolution medium inside the 
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Figure 15. Drying curves of ketoprofen‐loaded beads produced with 1.75% (w/w) alginate solution dried at different 
microwave irradiation levels: IV (‐▴‐); III (‐♦‐); II (‐●‐); I (‐▪‐); tray oven drying at 105°C (−⚬−) and room conditions drying 
(‐▴‐) are also reported. Mean ± SD; (n=6).
Figure 16. SEM microphotographs of K‐loaded alginate beads dried in different conditions: (a) at room conditions, (b) 
level I, and (c) level IV microwave irradiation.
Figure 17. (a) X‐ray diffraction patterns of blank alginate beads; K‐loaded alginate bead treated at different microwave 
power levels: (b) IV; (c) III; and (d) pure crystalline ketoprofen.
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alginate matrix in both SGF and SIF (complete release in about 2 h in SIF). A different behavior 
was observed for beads exposed to MW at level I. Drug release was significantly reduced in 
SGF, whereas it was prolonged and sustained until 6 h in SIF, as shown in Figure 18. The non‐
porous matrix and the structure integrity of the dried beads obtained with level I irradiation 
seem able to protect the drug in acidic medium and to achieve a prolonged/sustained release 
of ketoprofen in SIF, probably due to the interaction between drug and polymer matrix pro‐
moted by MW irradiation at level I [79].
2.2.2. Release characteristics of piroxicam‐loaded beads obtained by prilling‐dielectric treatments
Comparable results were obtained applying prilling/MW tandem technique to produce algi‐
nate beads loaded with piroxicam.
2.2.2.1. Results and discussion
Overall results from particles’ technological analysis showed high values of encapsulation 
efficiency (over 85%) and a very narrow dimensional distribution.
SEM analyses showed that MW at levels III‐IV drying process led to beads with small spots 
of crystalline piroxicam coming out of the surface (Figure 19b and c), whereas unspotted 
surface was obtained by MW irradiation at level I (Figure 19a). As reported in the literature, 
amorphous piroxicam shows a strong tendency to crystallize in either cubic (β) or needle form 
(α) [88]. The highest level of irradiation (MW level IV) allowed to obtain only the cubic form 
of crystalline PRX (Figure 19c). However, when MW level III was applied, both polymorphs 
(β cubic and α needle forms) were identified (Figure 19b).
Results of dissolution tests showed that the highest MW level (IV) produced a piroxicam 
intestinal dosage form with total PRX liberation in less than 1 h in simulated intestinal fluid. 
On the contrary, the lowest MW level (I) allowed to obtain a more sustained drug release pro‐
file (Figure 20). Differently from alginate/ketoprofen beads, where the presence of the drug 
(in amorphous or crystalline state) on the bead surface affected the release rate [85], in this 
case, drug release was not influenced by cubic or needle crystalline forms.
Figure 18. Release profiles of dried beads formulated with 1.75% (w/w) alginate solution and loaded with ketoprofen 
8% (w/w) dried at room temperature (‐▴‐) and by MW treatments at: level I (‐▴‐) and level IV (−●−). Mean ± SD; (n=6).
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The obtained results suggest that surface and inner characteristics of the alginate/piroxicam 
beads (roughness, network of cracks, and a fraction of crystalline piroxicam on beads surface) 
are strongly able to modulate the drug dissolution.
On the basis of these results, we can state that prilling/MW tandem technique can be used as a 
simple method to formulate alginate beads with tailored NSAIDs release depending on drug 
characteristics and MW irradiation level. Dielectric treatments compared to conventional 
methods offer several advantages such as faster drying kinetics leading to energy saving 
with low‐operative costs and the possibility to modulate drug release and dissolution profiles 
without affecting drug loading.
2.3. Prilling in tandem with supercritical fluid‐assisted drying
Another approach to develop dried beads with modified drug release behavior is represented 
by the use of prilling technique in tandem with supercritical fluids. Supercritical drying pro‐
cessing has also gained wide acceptance as an alternative to conventional drying techniques. 
Particularly, supercritical antisolvent extraction (SAE) overcomes the problems encountered 
with traditional drying methods and may preserve the nanoporous structure of the wet gel‐
beads leading to aerogels. Among the many possible supercritical fluids (SFs), carbon dioxide 
Figure 19. SEM microphotographs of beads’ surface (alginate 1.75% w/w; PRX 7% w/w) after MW irradiation at level I 
(a), III (b), and IV (c).
Figure 20. Drug release profile of piroxicam‐loaded beads (alginate 1.75% w/w and PRX 7% w/w) dried by MW at level 
I (‐▴‐) and level IV (‐●‐) compared to piroxicam raw material (‐▪‐). Mean±S.D. (n = 6).
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(CO
2
) is the most widely used. It has readily accessible critical points and as a process solvent 
offers the additional benefits of being nontoxic, nonflammable, environmentally acceptable, 
inexpensive, and can be used at a mild critical temperature suitable for processing thermally 
labile compounds. One major challenge for the preparation of alginate‐based aerogels is to 
eliminate the liquid solvent from the gel, while avoiding the collapse of the already exist‐
ing nanoporous structure with the subsequent shrinkage of the dried gel. Supercritical CO
2
‐
assisted drying is the most appropriate drying technique able to overcome these problems 
[89]. However, SC‐CO
2
 shows only a very limited affinity with water; therefore, in principle 
water‐based solution cannot be treated. Aerogel production technology comprises a series 
of steps such as formation of a polysaccharide water solution (hydrogel), gelation of the sol 
induced by cross‐linking promoters, replacement of water by a solvent (usually ethanol or 
acetone) and, finally, solvent elimination [90]. Various aerogel forms (monolithical cylinders, 
spheres, membranes, tubes, etc) may be produced by different techniques (moulding, extru‐
sion, and milling); however, beads are preferred for applications in pharmaceutics.
2.3.1. Ketoprofen‐loaded aerogel beads produced by tandem prilling/SAE
Recently, we designed and developed alginate‐based aerogel beads by using prilling in com‐
bination with SC‐CO
2
 processing [73]. As above mentioned, water‐based “materials” cannot 
be dried directly with SC‐CO
2
 due to the low solubility of water in the supercritical phase. 
To overcome this limitation, we tested either gelling process in alcoholic solution or solvent 
exchange pretreatment of hydrate beads to allow successful elimination of the solvent and 
to obtain aerogel formation. For this study, ketoprofen (K) was used as a model drug. Beads 
were produced by prilling and cross‐linked by calcium cations either in ethanol (sol → alco‐
gels) or in aqueous solutions (sol → hydrogels). In the latter case, solvent exchange was neces‐
sary to replace water by ethanol obtaining alcogels that were successively subjected to solvent 
extraction by SC‐CO
2
 leading to aerogels. Aerogel beads were designed to obtain a prompt 
release of the loaded drug and, consequently, a rapid onset of the analgesic effect, as required 
in postoperative pain [91, 92], dental surgery [93], renal and ureteral acute colic [94, 95].
2.3.1.1. Methods
Two series of beads were manufactured using 0.3 M CaCl
2
 in water or in ethanol as cross‐
linker solutions. All hydrated beads showed spherical shape (SC, 0.98 ± 0.01), smooth and reg‐
ular surface and a mean diameter ranging between 3.81 and 3.97 mm. Tiny white solid spots 
were present inside all loaded particles, whereas unloaded beads were almost transparent. 
Supercritical CO
2
 drying was performed by SAE laboratory apparatus at 150 bar and 37°C.
2.3.1.2. Results and discussion
In the selected drying conditions, reduced particle shrinkage was observed and the inter‐
nal porous texture of the parent hydrogel was preserved, as illustrated in the SEM image 
(Figure 21), where the nanofibrous alginate network is well visible. SC‐CO
2
 drying deter‐
mined a reduction of beads diameters ranging between 2.70 and 3.11 mm. As a comparison, 
drying process was also conducted using a homogenous amount of hydrated beads exposed 
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to room conditions and, alternatively, to air‐bulk heating (tray oven) at 105°C. As expected, 
both convective processing methods took long times (tray oven 4‐ h; room conditions 12–18 
h). Moreover, an extensive volume shrinkage was observed when convective drying meth‐
ods were used (diameter 1.8 mm with SD lower than 3%) due to the collapse of the polymer 
matrix during the slow solvent evaporation.
Encapsulation efficiency values were greater for beads subjected to conventional drying than 
for those treated with supercritical carbon dioxide without relevant differences between room 
conditions and tray oven. As previously reported, the transport phenomena involved in the 
supercritical fluid extraction may cause the extraction of small quantities of drug [96]; this 
effect may explain the observed decrease in EE. In detail, convective dried beads exhibited EE 
around 52 or 94% depending on ethanol or aqueous cross‐linking, respectively. In the same 
gelling conditions, SC‐CO
2
–treated beads showed EE around 6 or 59%.
The inner matrix structure was deeply influenced by different drying techniques. Supercritical 
treatment produced a nanoporous alginate matrix characterized by a network of nanopores 
with diameters around 200 nm. Convective drying leads to a compact matrix with less and 
larger pores where the nanofibrous structure was completely lost, as shown in Figure 21b. It 
is well known that one of the major challenges in aerogel production from hydrogels is the 
solvent elimination that must occur without inducing the collapse of the porous structure; 
in this regard, the fast elimination of ethanol from alcogels by SC‐CO
2
 processing is able to 
prevent the collapsing of the parent gel structure [97, 98].
More interestingly, the procedure for producing the alcogel‐influenced habitus of solid K into 
the inner matrix, as shown by SEM images (Figure 22) of cryo‐fractured dried particles. Cross‐
linking alginate in ethanol (Figure 22a) leads to crystal clusters of K drug embedded into the 
aerogel, beads from aqueous cross‐linking, and water replacement by ethanol (Figure 22b) 
showed only nanometric particles of amorphous K.
The dissolution profile of K from SC‐CO
2
–treated beads (Figure 23) presented an enhanced 
burst effect in SGF (more than 75% of the encapsulated drug in 30 min in acidic medium) 
for aerogels obtained cross‐linking the particles in aqueous CaCl
2
 and then replacing water 
with ethanol. Formulations cross‐linked in ethanol as well as crystalline material released 
less than 40% of K in the same time. The considerable increase of the drug dissolution rate for 
Figure 21. SEM microphotographs of ketoprofen‐loaded alginate beads inner matrix dried using different processes: 
supercritical CO
2
 treatment (a) and room conditions (b).
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formulations cross‐linked in water can be explained by the high porosity of the aerogel and 
by the increased surface‐volume ratio due to nanometric dimensions of the solid amorphous 
ketoprofen [99] embedded into the nanoporous structure.
In conclusion, prilling process in tandem with SC‐CO
2
‐assisted drying allows to produce 
alginate‐based aerogel. Drug loading capacity and encapsulation efficiency reached approxi‐
mately 59%. Interestingly, after SC‐CO
2
 drying, particles keep constant spherical shape and 
narrow dimensional range and retain the porosity of the parent hydrated gel‐matrix. The 
highly nanoporous drug carrier with high surface area provides enhanced and controlled 
fast release of ketoprofen. Formulations cross‐linked in water, and then replacing water with 
ethanol, improve significantly the dissolution rate of K, especially in simulated gastric fluid. 
High enhancement of the drug dissolution can be very useful in favoring drug liberation 
and absorption in order to obtain a rapid onset of the therapeutic effect as required in acute 
inflammation. Alginate‐based aerogel produced by prilling in combination with SC‐CO
2
–
assisted drying may be proposed as fast dissolving formulation for slightly soluble NSAIDs 
belonging to BCS class II.
Figure 23. Release profiles of K‐loaded alginate beads dried by SC‐CO
2
 treatment previously cross‐linked in ethanol 
(‐♦‐) or water (‐♢‐), exposed to room conditions (‐▴‐) in comparison to pure ketoprofen (‐▪‐). Mean ± SD; (n=6).
Figure 22. SEM microphotographs of cryo‐fractured ketoprofen‐loaded alginate beads dried by supercritical CO
2
 
previously cross‐linked in ethanol (a) or water (b).
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3. Conclusions
Particle engineering through prilling‐based techniques can be applied to widely used NSAIDs as 
ketoprofen and piroxicam to develop new drug delivery systems, which meet current therapeutic 
input and health demands. This approach allows to fit specific therapeutic needs of inflammatory‐
based diseases. Particularly, prilling technique in tandem with dieletric treatment at high MW level 
or with supercritical (SC‐CO
2
) drying allows to produce porous microparticles with high surface 
area able to enhance the dissolution rate of slightly soluble NSAIDs (BCS class II). These systems 
providing a fast drug release may promote a rapid therapeutic effect after oral administration, as 
required in acute pain and inflammation. Instead, using prilling in combination with conventional 
or dielectric drying at low MW levels, it is possible to obtain engineered particles with slower 
NSAIDs release compared to conventional and commercially available formulations. By oppor‐
tunely selecting carrier materials or gelling conditions or using additional technological actions 
such as enteric coating or capsular devices, it is possible to obtain chronotherapeutic drug delivery 
systems useful to treat EMPs. The potential benefits in chronotherapy of these systems were also 
confirmed using an in vivo model of inflammation. The control and strong delay of NSAIDs release 
make these drug products suitable to be taken at bed time and act in the early morning hours.
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